Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENIR Trial
2023-506512-40-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of vasopressin in acute kidney failure (AKF) and liver transplant (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Acute kidney injury stage (KDIGO) during first 7 postoperative days. Planned start Jan 2024; status: authorised.
02
Drugs
vasopressin
03
Conditions
acute kidney failure (AKF)liver transplant
Beyond the preview
Go deeper on 2023-506512-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506512-40-00.